Skip to main content
EMA Logo
  • Medicines
    Medicines

    • Search
    • Download
    • What we publish and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    Human regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Herbal products
  • Veterinary regulatory
    Veterinary regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    Committees

    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    News & events

    • News and press releases
    • Events
    • What's new
    • Committee highlights
    • Therapeutic areas: latest updates
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    Partners & networks

    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Academia
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    About us

    • What we do
    • Who we are
    • How we work
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • FAQs
    • Contacts

COVID-19 pandemic

All info here

QUICK LINKS

  • Latest updates
  • Vaccines
  • Treatments
  • Guidance for developers and companies
  • Highlights of the Safety Committee: May 2023
    PRAC highlights October 2021
    MEDICINES |COMMITTEES

    Highlights of the Safety Committee: May 2023

  • Highlights of the Safety Committee: May 2023
    PRAC highlights October 2021
    MEDICINES |COMMITTEES

    Highlights of the Safety Committee: May 2023

    The PRAC started a review of hydroxyprogesterone medicines and issued a reminder on the restrictions in the use of fluoroquinolone antibiotics

  • End of COVID-19 public health emergency
    Executive director of EMA
    COVID-19 |Statement

    End of COVID-19 public health emergency

  • End of COVID-19 public health emergency
    Executive director of EMA
    COVID-19 |Statement

    End of COVID-19 public health emergency

    EMA's Executive Director, Emer Cooke, issues a statement after the end of the Public Health Emergency of International Concern (PHEIC) for COVID-19 was declared by the WHO.

  • Revision of transparency rules for clinical trials
    Slider on clinical trials rules
    Clinical Trials |Public consultation

    Revision of transparency rules for clinical trials

  • Revision of transparency rules for clinical trials
    Slider on clinical trials rules
    Clinical Trials |Public consultation

    Revision of transparency rules for clinical trials

    EMA has opened a public consultation to review the transparency rules for the publication of information on clinical trials submitted through the CTIS in the EU

  • Single-arm clinical trials as pivotal evidence for the authorisation of medicines
    Clinical trials |Regulatory

    Single-arm clinical trials as pivotal evidence for the authorisation of medicines

  • Single-arm clinical trials as pivotal evidence for the authorisation of medicines
    Clinical trials |Regulatory

    Single-arm clinical trials as pivotal evidence for the authorisation of medicines

    EMA has opened a public consultation to discuss how data from single-arm clinical trials can support marketing authorisation applications for medicines in the EU

Search for medicines
Search for information on human, veterinary or herbal medicines.
What's new
Find all the latest news and updates published on this website in one place.
FAQs
Find answers to the most frequently asked questions we receive.

Latest news

  • List item
    12/05/2023

    Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 12 May 2023

    Review of hydroxyprogesterone started EMA has started a review of medicines containing hydroxyprogesterone following concerns about the safety and effectiveness of these medicines. In the EU, these medicines are available as hydroxyprogesterone...

  • List item
    12/05/2023

    Fluoroquinolone antibiotics: reminder of measures to reduce the risk of long-lasting, disabling and potentially irreversible side effects

    EMA’s safety committee, PRAC, is reminding healthcare professionals that the use of fluoroquinolone antibiotics, given by mouth, injection or inhalation, is restricted due to the risk of disabling, long-lasting and potentially irreversible side...

  • List item
    10/05/2023 COVID-19

    EMA and European medicines regulatory network lift COVID-19 business continuity status

    EMA and the European medicines regulatory network are lifting their respective COVID-19 business continuity measures after successfully handling the unprecedented operational challenges posed by the pandemic. This was foreseen in EMA’s workplan for...

  • List item
    08/05/2023 COVID-19

    Statement from Emer Cooke on the end of the COVID-19 public health emergency

    On Friday, the WHO Director General declared an end to the Public Health Emergency of International Concern (PHEIC) for the disease caused by the coronavirus SARS-CoV-2. I welcome this important milestone and would like to share some thoughts about...

  • List item
    05/05/2023

    EMA business hours on Europe Day, Tuesday 9 May

    The European Medicines Agency's (EMA) office is closed from 18:30 on Monday 8 May until 07:30 on Wednesday 10 May 2023. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600...

  • List item
    03/05/2023

    Review of transparency rules for the EU Clinical Trials Information System (CTIS)

    EMA has opened a public consultation to review the transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System (CTIS) in the European Union (EU). Stakeholders are invited to send...

  • Load more news

Information for you

Patients and carers
Featured news and updates for patients and carers
Healthcare professionals
Featured news and updates for healthcare professionals, including doctors, nurses and pharmacists
Animal health professionals
Featured news and updates for animal health professionals and users of veterinary medicines such as pet owners
Pharmaceutical industry
Featured news and updates for pharmaceutical industry stakeholders active in the human and veterinary medicines fields
Media
Featured news and updates for journalists with a professional interest in the development and availability of medicines in the European Union
Academia
Featured news and updates for European academics and researchers in the field of medicine development

Key content

  • List item

    Product emergency hotline

  • List item

    UK’s withdrawal from the EU

  • List item

    PRIME: Priority medicines

  • List item

    Pharmacovigilance (safety monitoring)

  • List item

    Data on medicines

  • List item

    Clinical data publication

  • List item

    Careers

Services & databases

  • List item

    Clinical Trials website

  • List item

    Account Management portal

  • List item

    eSubmission

  • List item

    EudraVigilance (human)

  • List item

    EudraVigilance Veterinary

  • List item

    Veterinary Medicines information website

  • List item

    Suspected adverse drug reactions database

  • List item

    Clinical data

  • List item

    SPOR data management services

  • List item

    Service Desk

  • List item

    IRIS platform

  • List item

    Public register of parallel distribution notices

  • List item

    European Vaccination Information Portal

How does EMA work?

  • List item

    What we do

  • List item

    Our role in authorisation of medicines

  • List item

    Who we are

  • List item

    Our scientific experts

  • List item

    How we work

  • List item

    What we publish

Product emergency hotline
outside working hours
  • About us
  • What we do
  • Careers
  • Committees
  • Regulatory network
  • Languages
  • Frequently asked questions
  • Glossaries
  • About this website
  • Privacy
  • Search tips
  • Access to documents
  • Contacts
  • Send a question
  • EMA Service desk (system support)

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us

Postal address and deliveries

Business hours and holidays

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
RSS feed Twitter YouTube LinkedIn
© 1995-2023 European Medicines Agency
European Union agencies network
European Union agencies network
An agency of the European Union
European Union flag